On October 15, 2025 OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, reported that its latest research has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2025 Congress, taking place October 17-21 in Berlin, Germany.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study, "A plasma proteomics-based model optimizes first-line treatment decisions for metastatic melanoma," explores the potential of the company’s PROphet model—originally developed and validated in non-small cell lung cancer (NSCLC)—to inform treatment selection in melanoma, a setting where biomarkers to guide clinical decisions remain limited.

Poster Presentation

Title: A plasma proteomics-based model optimizes first-line treatment decisions for metastatic melanoma
Presenting Author: Ryan Sullivan, MD, Massachusetts General Hospital, Boston, MA, USA
Session Date & Location: October 18, 2025
Session: Melanoma and other skin tumours
Poster Number: 1680P

Study Highlights and Conclusions

PROphet is a plasma proteomic platform that leverages a panel of 388 Resistance-Associated Proteins (RAPs) to compute the probability of clinical benefit (CB) and stratify patients as PROphet POSITIVE or PROphet NEGATIVE. In NSCLC, the test has demonstrated predictive value for patient outcomes with anti–PD(L)1-based therapy.

In this real-world prospective observational study, pre-treatment plasma samples were collected from 248 patients with metastatic melanoma treated with anti-PD1 monotherapy (pembrolizumab or nivolumab) or anti-PD1 + anti-CTLA4 combination (ipilimumab + nivolumab) were analyzed.

Key findings include:

Prognostic power: The PROphet model successfully stratified melanoma patients, with PROphet POSITIVE patients showing a significant survival advantage over PROphet NEGATIVE patients (HR = 0.42, p < 0.001).
Predictive for anti-PD1 therapy: The strongest effect was observed in patients treated with anti-PD1 monotherapy, underscoring the model’s predictive utility in this setting.
Independent factor: Multivariate analysis confirmed PROphet remained significant even after adjusting for LDH, age, sex, and other variables (HR = 0.30, p = 0.04).
Treatment guidance:
PROphet POSITIVE patients (66% of cohort) achieved comparable survival with anti-PD1 monotherapy and anti-PD1 + anti-CTLA4 therapy (HR = 0.9, p = 0.35). This suggests monotherapy may be sufficient, sparing patients unnecessary toxicity from combination regimens.
PROphet NEGATIVE patients demonstrated a trend toward improved survival with the combination approach (HR = 0.64, p = 0.065).
"Selecting the right treatment modality for melanoma patients remains a significant clinical challenge," said Michal Harel, PhD, VP Translational Medicine at OncoHost. "Our findings demonstrate how plasma proteomics can provide actionable insights that inform treatment decisions and bring us closer to truly personalized care for patients facing melanoma."

(Press release, OncoHost, OCT 15, 2025, View Source [SID1234656680])

On October 15, 2025 Jacobio Pharma (1167.HK) reported that its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd. ("Beijing Jacobio"), has entered into a Capital Increase and Equity Transfer Agreement with Oceanpine Capital and an industry partner. Under the agreement, Oceanpine Capital will acquire 80% equity interest in Beijing Jacoray Pharmaceutical Technology Co., Ltd. ("Jacoray") for a total consideration of RMB 200 million (comprising RMB 125 million as the upfront payment and an additional RMB 75 million as a second instalment milestone payment). Upon completion, Beijing Jacobio, Oceanpine Capital, and the industry partner will hold 10%, 80%, and 10% of Jacoray, respectively.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jacoray is the project company for Jacobio’s early-stage cardiovascular research program. The transaction aligns with Jacobio’s strategic focus on developing innovative oncology therapies—including KRAS and iADC —by optimizing capital allocation, enhancing operational efficiency, and adopting a risk-sharing model to retain long-term project value. Proceeds from the transaction will primarily support R&D, production, and commercialization of Jacobio’s Pan-KRAS inhibitor and other oncology assets.

Mr. Dave Chenn, Founder, CEO and Managing Partner of Oceanpine Capital, said: "Jacobio demonstrates outstanding scientific strength and strategic focus in oncology innovation. Oceanpine Capital looks forward to partnering with Jacobio to advance the globalization of China’s biotech innovation."

Dr. Yinxiang Wang, Chairman of Jacobio, said, "This partnership with Oceanpine Capital strengthens our strategic focus on oncology innovation and reinforces our commitment to advancing next-generation cancer therapies."

(Press release, Jacobio Pharmaceuticals, OCT 15, 2025, View Source [SID1234656679])

On October 15, 2025 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported new and updated data from its advancing oncology pipeline will be shared in seven abstracts at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2025 Meeting, taking place from October 17-21 in Berlin, Germany. Highlights include new Phase 3 C-POST data on an every 6-week dosing regimen for the PD-1 inhibitor Libtayo (cemiplimab) as adjuvant treatment for cutaneous squamous cell carcinoma (CSCC) with a high risk of recurrence.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our oncology presentations at ESMO (Free ESMO Whitepaper) represent important progress toward expanding options for people with difficult-to-treat cancers," said Israel Lowy, M.D., Ph.D., Clinical Development Unit Head, Oncology, at Regeneron. "Notably, we look forward to sharing new data on a patient-centric every 6-week dosing option from our C-POST Phase 3 trial, which recently supported the FDA approval of Libtayo as the first immunotherapy for adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation."

The new safety and pharmacokinetic data from C-POST being presented at ESMO (Free ESMO Whitepaper) showcase a patient-centric approach to dosing. Patients received either adjuvant therapy with Libtayo or placebo intravenously, starting with 350 mg every 3 weeks for 12 weeks. The majority of patients were switched to every 6-week dosing after the initial 12 weeks, and the remaining patients continued with dosing every 3 weeks throughout the trial. Treatment continued until disease recurrence, unacceptable toxicity, or up to 48 weeks of treatment. Efficacy, pharmacokinetics and immunogenicity were similar across both regimens. The safety profile of Libtayo as adjuvant treatment of patients with CSCC at high risk of recurrence after surgery and radiation is consistent with the known safety profile for Libtayo monotherapy in advanced cancers.

The full list of Regeneron presentations at ESMO (Free ESMO Whitepaper) includes:

Abstract Title Abstract Presenter Session Date/Time
(CET)
Libtayo skin cancer
Analysis of second primary cutaneous squamous cell carcinoma (CSCC) tumors (SPTs) reported during the C-POST trial, a randomized phase 3 study of adjuvant cemiplimab vs placebo for high-risk CSCC Mini-oral
presentation: 1603MO

Danny
Rischin Saturday,
October 18,
14:45-16:15
Adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma: Evaluating dosing intervals in a phase 3 trial Poster
presentation:
1660P

Danny
Rischin Monday,
October 20,
12:00-12:45
CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective, non-interventional study of the safety and effectiveness of cemiplimab in immunocompromised/immunosuppressed (IC/IS) patients with advanced cutaneous squamous cell carcinoma (CSCC) at 18 months’ follow-up Poster
presentation:
1666P

Soo J.
Park Monday,
October 20,
12:00-12:45
Libtayo lung cancer
Association between patient-reported outcomes (PROs) and overall survival (OS) in aNSCLC patients treated with first-line (1L) cemiplimab-based therapy Poster
presentation:
1862P

David R.
Gandara Saturday,
October 18,
12:00-12:45
Ubamatamab
Randomized Phase 2 study of ubamatamab ± cemiplimab in patients (pts) with platinum-resistant ovarian cancer (OC) Poster
presentation:
1078P

Jung-Yun
Lee Saturday,
October 18,
12:00-12:45
REGN7075
Mitigating infusion-related reactions (IRRs) with cetirizine and montelukast in patients (pts) receiving REGN7075, an EGFRxCD28 bispecific antibody (bsAb) Poster
presentation:
1558P

Neil H.
Segal Sunday,
October 19,
12:00-12:45
Additional presentations
Predicting real-world overall survival in advanced melanoma using machine learning Poster
presentation: 1632P

Fei
Wang Monday,
October 20,
12:00-12:45

The potential use of ubamatamab described above is investigational, and its safety and efficacy have not been evaluated by any regulatory authority.

(Press release, Regeneron, OCT 15, 2025, View Source [SID1234656677])

On October 15, 2025 Propanc Biopharma, Inc. ("Propanc" or the "Company") reported it has entered into a strategic financing agreement of up to $100 million with Hexstone Capital LLC ("Hexstone"), a family office that has invested in a significant number of Digital Asset Treasury (DAT) companies across a range of digital assets including BTC, ETH, SOL, DOGE, ATH, OG, and INJ. "We are delighted to enter into this strategically important transaction with Hexstone Capital," said James Nathanielsz, Chief Executive Officer of Propanc. "This financing will allow us to accelerate the development of our clinical pipeline and leverage Hexstone’s previous investments in companies that have also built out Digital Asset Treasuries. Our goal is to grow our treasury to a value of $100 million or more within the next twelve months. In less than five years, DAT companies have evolved from being market curiosities to becoming significant players in the digital asset ecosystem. We believe we are well-positioned to capitalize on this trend and generate both short- and long-term value for shareholders."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Transaction Overview

Under the terms of the agreement, Propanc will issue 100 shares of newly designated Series C Convertible Preferred Stock, each with a par value of $0.01 and an initial stated value of $10,000, resulting in an initial investment of $1 million.

The Preferred Stock is convertible into Common Stock at an initial conversion price of $5.00 per share, representing a 280% premium over the Company’s recent closing price of $1.78. The conversion terms include variable alternative conversion prices and are subject to a 4.99% beneficial ownership limitation, as detailed in the Company’s filings with the U.S. Securities and Exchange Commission (SEC).

Additionally, Propanc will issue 9,900 Warrants to Hexstone, each entitling the purchase of one share of Preferred Stock at $9,999.99, totaling up to $99 million in potential funding. The Warrants are exercisable, immediately, and will remain valid for 12 months. Subject to equity conditions and beneficial ownership limits, the Company may call up to 500 Warrants per calendar month at $0.01 each, allowing up to $5 million in Preferred Stock per month—less any Warrants already exercised by Hexstone during that period.

Further details can be found in the Company’s Form 8-K filed with the SEC and accessible at www.sec.gov.

(Press release, Propanc, OCT 15, 2025, View Source [SID1234656676])

On October 15, 2025 PharmaMar Group (MSE: PHM) reported it has received a milestone payment of $50 million from Jazz Pharmaceuticals plc (Nasdaq:JAZZ) related to the full approval granted on October 2nd of this year from the U.S Food and Drug Administration (FDA) for Zepzelca (lurbinectedin) in combination with atezolizumab (Tecentriq) as a first-line maintenance treatment for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In December 2019, PharmaMar entered into an exclusive license agreement with Jazz Pharmaceuticals for lurbinectedin in the United States.

(Press release, PharmaMar, OCT 15, 2025, View Source [SID1234656675])